GC Biopharma WellBeing, Boryung target secondary hospitals for Laennec
AI Summary- GC Biopharma WellBeing and Boryung signed a co-promotion agreement for Laennec sales.
- 226 patients at 18 South Korean institutions joined Laennec’s Phase 3 trial.
- GC Biopharma WellBeing plans to seek intravenous-administration approval this year.